Use of Opioid Overdose Deaths Reported in One State's Criminal Justice, Hospital, and Prescription Databases to Identify Risk of Opioid Fatalities

TY - JOUR

T1 - Use of Opioid Overdose Deaths Reported in One State's Criminal Justice, Hospital, and Prescription Databases to Identify Risk of Opioid Fatalities

AU - Eisenberg, Matthew D.

AU - Saloner, Brendan

AU - Krawczyk, Noa

AU - Ferris, Lindsey

AU - Schneider, Kristin E.

AU - Lyons, B. Casey

AU - Weiner, Jonathan P.

N1 - Funding Information: Methods | We undertook a retrospective analysis of safety advisories issued by the US Food and Drug Administration (FDA), Health Canada (HC), the UK Medicines and Healthcare products Regulatory Agency (MHRA), and the Australian Therapeutic Goods Administration (TGA) from January 1, 2007, to December 31, 2016. Safety advisories were defined as notifications to prescribers and/or the public about a potential or confirmed drug risk, excluding issues of production quality, shortages, or overdoses. We obtained advisories from regulators’ websites (current and archived). This project did not fall within the scope of the National Statement on Ethical Conduct in Human Research because all included data are from publicly available documents. Therefore, according to University of Sydney Research Code of Conduct, ethics approval was not required. Funding Information: Funding/Support: This study was funded by a Harold Rogers Prescription Drug Monitoring Program grant awarded by the US Department of Justice, Office of Justice Programs, Bureau of Justice Assistance, aimed at improving prescription drug monitoring programs to prevent and reduce misuse and abuse of prescription drugs. The Maryland Department of Health, Behavioral Health Administration, was awarded the grant in partnership with the Center for Population Health Information Technology at the Johns Hopkins Bloomberg School of Public Health for data analyses and subject matter expertise and the Chesapeake Regional Information Systems for our Patients to link the data sets. Mss Krawczyk and Schneider were supported by T32 grant 5T32DA007292-25 from the National Institute on Drug Abuse. Funding Information: Funding/Support This work was supported by a grant from the Milbank Memorial Fund and was supported through the RAND Center of Excellence on Health System Performance, which is funded by cooperative agreement 1U19HS024067-01 between the RAND Corporation and the Agency for Healthcare Research & Quality.

PY - 2019/7

Y1 - 2019/7

UR - http://www.scopus.com/inward/record.url?scp=85064275964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064275964&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2018.8757

DO - 10.1001/jamainternmed.2018.8757

M3 - Letter

C2 - 30985862

AN - SCOPUS:85064275964

SN - 2168-6106

VL - 179

SP - 980

EP - 982

JO - JAMA internal medicine

JF - JAMA internal medicine

IS - 7

ER -